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Abstract
Objectives: To evaluate the incidence and risk factors for lymphedema associated with surgery
for gynecologic malignancies on GOG study 244.
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Methods: Women undergoing a lymph node dissection for endometrial, cervical, or vulvar
cancer were eligible for enrollment. Leg volume was calculated from measurements at 10-cm
intervals starting 10 cm above the bottom of the heel to the inguinal crease. Measurements were
obtained preoperatively and postoperatively at 4–6 weeks, and at 3-, 6-, 9-, 12-, 18-, and 24months. Lymphedema was defined as a limb volume change (LVC) ≥10% from baseline and
categorized as mild: 10–19% LVC; moderate: 20–40% LVC; or severe: >40% LVC. Risk factors
associated with lymphedema were also analyzed.
Results: Of 1054 women enrolled on study, 140 were inevaluable due to inadequate
measurements or eligibility criteria. This left 734 endometrial, 138 cervical, and 42 vulvar patients
evaluable for LVC assessment. Median age was 61 years (range, 28–91) in the endometrial, 44
years (range, 25–83) in the cervical, and 58 years (range, 35–88) in the vulvar group. The
incidence of LVC ≥10% was 34% (n=247), 35% (n=48), and 43% (n=18), respectively. The peak
incidence of lymphedema was at the 4–6 week assessment. Logistic regression analysis showed a
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decreased risk with advanced age (p=0.0467). An exploratory analysis in the endometrial cohort
showed an increased risk with a node count >8 (p=0.033).
Conclusions: For a gynecologic cancer, LVC decreased with age greater than 65, but increased
with a lymph node count greater than 8 in the endometrial cohort. There was no association with
radiation or other risk factors.
Keywords
endometrial cancer; vulvar cancer; cervical cancer; lymphedema; lymphadenectomy; staging

INTRODUCTION
Author Manuscript
Author Manuscript

In 2012, when GOG 244-The Lymphedema and Gynecologic Cancer study was opened, a
lymph node assessment was considered to be integral part of staging for endometrial,
cervical and vulvar cancer patients and it remains so today [1–3]. These staging procedures
are associated with lymphedema of the lower extremity (LLE), one of the most challenging
complications associated with the diagnosis and treatment of a gynecologic cancer. It is
commonly reported that an estimated 20% to 60% of gynecologic cancer patients will
struggle with lymphedema [4–6]. The true incidence of lymphedema in the general
population, as well as in gynecologic cancer patients, is difficult to determine in part because
there are many way to measure it and therefore define it [7]. Most of the previous
lymphedema analyses on patients with a gynecologic malignancy have been limited, largely
retrospective, and frequently via a survey questionnaire [6, 8, 9]. In recent reports, LLE has
been objectively measured as a change in bioimpedance [10, 11] or a change in limb volume
as compared to the opposite leg [10]. The various assessment and diagnostic methods in
these published reports have been inconsistent, which contributes to the wide range in
reported incidence.

Author Manuscript

Gynecologic Oncology Group (GOG) study 195, a randomized trial evaluating the use of a
fibrin sealant in the inguinal incisions of vulvar cancer patients, was one of the initial efforts
to prospectively evaluate for lymphedema in a gynecologic oncology population [12]. In that
study, circumferential measurements were used to assess limb volume change (LVC), which
was then used as a surrogate for lymphedema. Patients were evaluated for LVC as
determined by three measurements in the lower, middle and upper leg, which were
compared to preoperative baseline measurements. Although the study was negative for the
use of a fibrin sealant to impact the incidence of lymphedema, GOG 195 identified that the
incidence of lymphedema was 60–67% in the study and control arm, respectively.
Concurrent with this high incidence of lymphedema was a concern that medical professional
awareness of lower extremity lymphedema was less than awareness for upper extremity
lymphedema as evidence by being less likely to receive an early referral to a lymphedema
specialist [13]. These factors initiated a broader GOG interest in LLE and an intent to
investigate lymphedema across a larger number of endometrial, cervical and vulvar cancer
patients. Submersion with water displacement has been considered the gold standard for
evaluating LVC, a surrogate for lymphedema [14]. The technique, however, is laborintensive, complicated, and not available in many communities. More recently, sequential
circumference measurements in the upper extremity have demonstrated excellent intra- and
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inter-observer reliability, and have yielded results statistically indistinguishable from those
of the water displacement method[15–17]. The reported upper extremity correlation between
the volumes measured with circumferential measurements and water displacement
measurement is 0.99 [18]. The current study expanded on the experience from GOG-195
and increased the number of leg measurements from three locations along the limb to every
10 cm to improve the ability to detect a change in limb volume in the lower extremity. This
study expanded on the clinical variables collected during GOG-195 to allow for any
confounding or exploratory relationships to LLE. This study also incorporated patient selfreported symptoms associated with the development of LLE so that more than one method
was used to assess patients. These self-reported symptoms have been well documented in the
upper extremity lymphedema literature [19, 20]. The Gynecologic Cancer Lymphedema
Questionnaire (GCLQ) has an internal consistency reliability of 0.95 [21] and underwent
additional adaptation and validation for inclusion in this trial.

Author Manuscript

The primary management of endometrial, cervical and vulvar cancer has included some type
of regional nodal assessment that is commonly associated with increasing the risk of
lymphedema[22]. It is believed that this surgical disruption of normal lymphatic channel
causes a pooling of extracellular fluid distal to the dissection that is further complicated by
the dependent position of the lower extremities. At the time it opened, this study
incorporated gynecologic cancers where there was consensus in the nodal assessment such
as the pelvic lymphadenectomy for cervical and endometrial cancer, and the inguinal
lymphadenectomy for vulvar cancer [2, 3, 23]. Ovarian and other peritoneal malignancies
were not included in this study as the role of primary retroperitoneal nodal assessment was
less clear.

Author Manuscript

The primary objective of this study was to prospectively evaluate the incidence of LLE in
patients undergoing primary surgery with a concurrent lymphadenectomy for a gynecologic
malignancy of the cervix, endometrium, or vulva. Multiple variables were collected from the
surgery and any adjuvant therapy to be analyzed for their relationship to lymphedema of the
lower extremity.

METHODS

Author Manuscript

The LEG Study (GOG-244) was a multi-institutional, prospective study of women with
newly diagnosed endometrial, cervical, or vulvar cancer who underwent a surgery that
included a lymphadenectomy as primary intervention, with the intent of 2 years of followup. Eligible patients had to satisfy the following criteria: 1) planned for hysterectomy/
bilateral salpingo-oophorectomy (BSO) and pelvic lymphadenectomy +/− para-aortic node
sampling via open or laparoscopic technique for clinical stage I-II uterine carcinoma; 2)
planned for radical hysterectomy or trachelectomy and pelvic lymphadenectomy +/− paraaortic node sampling via open or laparoscopic technique for clinical stage IA-IIA cervical
carcinoma; or 3) planned for definitive surgery for primary stage I-IV vulvar cancer,
consisting of radical vulvectomy or radical local excision with concurrent unilateral or
bilateral inguinal or inguinal-femoral lymphadenectomy. Participants were able to receive
therapy (radiation and/or chemotherapy) after primary surgical treatment.
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All study participants signed written informed consent and were enrolled between June 4,
2012 and November 17, 2014. Patients underwent lower limb volume measurements at
baseline (within 14 days prior to surgery), at 4–6 weeks, and 3-, 6-, 9-, 12-, 18-, and 24months after surgery. Cohort variables such as medical co-morbidities and cancer treatments
were collected, as well as known, suspected, and possible risk factors for the development of
LLE. In addition, participants completed patient-reported outcomes (PRO) assessments of
LLE symptoms (GCLQ), quality of life (QoL), and psychological adjustment and function
during the same time points. The PRO and GCLQ data are reported in the accompanying
manuscript by Carter et al. The other assessments will be in a future publication.
Measurements
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Standard measurements of limb volume involved taking bilateral circumferential
measurements at 10-cm intervals starting 10 cm above the bottom of the patient’s heel (with
the heel flexed at 90 degrees to the leg) and continued to the inferior aspect of the inguinal
crease of the groin [24]. The last measurement was taken at the last 10-cm interval below the
inguinal crease. Measurements were obtained twice at each level and verified, allowing for a
variance of 1.0 cm, for human error. The hands-on training programs for participating
research associates were coordinated and performed during semi-annual group meetings and
was required prior to an institution enrolling any patients. The training continued until the
trainee could perform all measurements to within 1 cm of the trainer. Leg volumes were
calculated from the circumferential measurements based on the formula for a truncated
cone: V = (h)(C2 + Cc + c2)/12(π) (where h = height of the segment; C = circumference at
top of segment; c = circumference at bottom of segment) [18, 25]. The leg volume was
determined by the summation of each truncated cone volume. To be classified as
lymphedema, a LVC of at least 10% was required [26]. Additionally, lymphedema was
further categorized as mild: 10–19% excess limb volume; moderate: 20–40% excess limb
volume; or severe: >40% excess limb volume [27]. To be considered evaluable for general
analysis, the patient needed preoperative measurements and at least one postoperative
measurement. Treatment for lymphedema was allowed during the follow-up. The patientreported diagnosis of lymphedema and types of lymphedema treatment were collected as
part of the PRO data (see Carter et al. in the accompanying manuscript).
As yet another method of lymphedema surveillance, the Stemmer’s sign was assessed during
each of the data collection points concurrent with the measurements. The Stemmer’s sign
was assessed by pinching a fold of skin at the base of the second toe on each foot.
Stemmer’s sign was present and indicative of lymphedema when a skin fold could not be
raised.

Author Manuscript

Statistical Analysis
The incidence of lymphedema was calculated as the number of patients demonstrating at
least a 10% increase in limb volume at any of the time points for which they had a
measurement taken over 24 months. For a patient to be evaluable for the risk factor analysis,
the per-protocol criteria required that at least 5 of the 8 measurements were obtained
(preoperative measurement and at least 4 postoperative measurements). The protocol power
analysis was designed in anticipation that some patients would be lost to follow-up over
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time. Protocol eligibility criteria for risk analysis required a preoperative measurement and
at least 4 postoperative measurements, not necessarily in sequence. The power analysis was
performed based on the predicted incidence of LLE. Logistic regression was used for the
comparison of the potential risk factors, with the incidence of lymphedema as the primary
outcome variable. The Mantel-Haenszel test was used to evaluate the Stemmer’s sign. A pvalue less than 0.05 was considered significant.

RESULTS

Author Manuscript
Author Manuscript

Of 1054 women enrolled on study, 54 were excluded for not meeting various eligibility
criteria, the majority involving the omission of lymphadenectomy during the surgical
procedure (n=44). Of the 1000 remaining patients, 86 were inevaluable due to inadequate or
missing measurements. This left 734 endometrial, 138 cervical, and 42 vulvar cancer
patients evaluable for LVC assessment (Figure 1). Median age was 61 years (range, 28–91)
in the endometrial cohort, 44 years (range, 25–83) in the cervical cohort, and 58 years
(range, 35–88) in the vulvar cohort. Overall patient characteristics are presented in Table 1
with additional characteristics for the endometrial cohort presented in Table 2 (online only).
Clinical comorbidities identified during follow-up are presented in Table 3, with
postoperative infection in the vulvar cohort being the most commonly reported at 26%. The
per-protocol definition of lymphedema was an LVC ≥10%. The incidence of LVC ≥10% was
34% (n=247) in the endometrial, 35% (n=48) in the cervical, and 43% (n=18) in the vulvar
cohorts (Table 4). For the endometrial cancer patients with LVC ≥10%, LVC severity was
considered mild in 22.8% (n=167), moderate in 9.5% (n=70), and severe in 1.4% (n=10).
Similarly, severity was considered mild in 22.5% (n= 31), moderate in 10.9% (n=15), and
severe in 1.5% (n=2) of the cervical cancer patients. LVC severity was mild in 28.6%
(n=12), moderate in 11.9% (n=5), and severe in 2.4% (n=1) of the vulvar cancer patients.
The peak incidence of LVC increase was at the 4–6 week assessment point. (Table 5 online
only), but new patients with a LVC ≥ 10% were identified at each point of follow-up through
two years. However, there was a fairly persistent loss of patients to follow-up during the
protocol; only 54% of the endometrial cancer patients, 48% of the cervical cancer patients,
and 40% of the vulvar cancer patients completed the 24 months of follow-up (Table 6).
The Stemmer’s sign was used as secondary method to evaluate for potential lymphedema. A
comparison between assessment with Stemmer’s sign and LVC ≥10 showed no significant
correlation between the Stemmer’s sign and lymphedema in this study (Graph 1 Online
only).
Risk Factor Analysis

Author Manuscript

A total of 541 endometrial, 98 cervical, and 31 vulvar cancer patients had the preoperative
and at least 4 postoperative measurements. Because of the small numbers in the cervical and
vulvar cohorts, only the endometrial cohort was analyzed for different risk factors. The
logistic regression analysis for these risk factors in the endometrial cohort is shown in Table
7. An increasing age was the only risk factor identified to be significantly associated with
lymphedema in this cohort. The analysis showed that the risk of lymphedema decreased with
advancing age, with an odds ratio of 0.816 (95% CI, 0.670–0.994). All other risk factors,
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including a comparison of surgical approach (open, laparoscopic or robotic), were not
significant for the endometrial cohort, or the cervical cohort, when it was evaluated in an
exploratory fashion. Radiation was further evaluated, as it is commonly associated with
lymphedema. The timing of the identification of the LVC in the radiated cohort was
important. If the LVC preceded the onset of radiation, the patient was excluded from that
risk factor evaluation. In this analysis, external beam radiation was also not associated with
lymphedema. The transitory nature of LVC was identified in the endometrial cohort with
more than 5 measurements. In this group, 59% (n=320) did not have a LVC ≥10% and 19%
(n=100) had only one transition in that they developed and maintained a LVC ≥10% for the
remainder of the study. But, 15% (n=79) of this group had two transitions where they
manifested an LVC ≥10%, but then had an episode of LVC < 10% before they had a future
measurement with LVC ≥10%. Of these patients, only 9 were documented to be “in
treatment”. Approximately 8% (n=42) of this endometrial cohort had more than two
transitions (range 3–6) where there they had episodes of LVC < 10% followed by a LVC
≥10% (Table 8 Online only). Venous insufficiency and orthopedic procedures were
monitored, but occurred so infrequently, that an odds ratio could not be reliably established.

Author Manuscript

Lymph node count was evaluated in relation to an LVC ≥10% in the endometrial group, the
largest cohort. For this descriptive analysis of node count, a dichotomy of ≤ 8 nodes
compared to >8 nodes was explored. This number was selected based on the bilateral
removal of at least one node from each of the four critical node basins (external and
common iliac, obturator, and periaortic). The variables that were included for this
exploratory analysis were endometrial cancer, surgical approach, stage, race, age,
performance status, serum albumin, nodes count (over/under 8), presence of metastatic
nodes, radiation, chemotherapy, use of heparin, and use of compression stockings. Patients
that had a post-surgical infection, vascular insufficiency, or VTE were excluded from the
exploratory analysis. In this endometrial cohort, only a node count >8 was significantly
related to increased severity of lymphedema, with an odds ratio of 2.031 (95% CI, 1.058–
3.901; p=0.0333). Of the endometrial cancer patients who had ≤8 nodes removed, 23.2%
(19/82) developed lymphedema, as defined by a ≥10% increase in limb volume. This
compared to 35.0% (228/652) in those patients who had more than 8 nodes removed. A
similar analysis with the smaller cervical cohort did not show a significant relationship.

Author Manuscript

There were too few vulvar cancer patients enrolled for risk factor analysis. To be eligible for
this protocol, the vulvar cancer patients needed a clinical indication for a full inguinal
lymphadenectomy. This protocol was initiated after the adaptation of the vulvar sentinel
lymph node approach, which contributed to the low enrollment among these patients. The
protocol was later amended to exclude any additional vulvar patients in an attempt to
increase the enrollments of the endometrial and cervical patients.
Measurements
The study was conducted at 52 enrolling parent institutions with 72 affiliates as well as
NCORP sites. There was a median of 4 research associates involved in performing
assessments (range 1–26). The protocol defined the method of leg measurement to be
utilized. As described in the methods section above, extensive training was implemented
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prior to initiating enrollment. Yet, 32% of the patients had some variance in leg length
reported during the study. For statistical analysis, the leg length in these patients was
truncated to the longest length where there were consistent measurements across all of the
intervals of follow up in these circumstances. The protocol also defined that each
circumferential measurement would be obtained twice and verified, allowing for up to a 1.0
cm variance in each of the paired measurements. Yet, of the 1054 patients in this study,
11.3% had greater than a 1.0 cm difference in the paired values reported at some point in the
study. Of these, 10 patients had measurements that exceeded > 1.5 cm in the paired
measurements and these measurement assessments were excluded from the analysis.

DISCUSSION

Author Manuscript
Author Manuscript

Lymphedema is defined as a chronic, dynamic condition in which protein-rich fluid
accumulates in the superficial tissues. Lymphedema can be problematic causing discomfort,
or heaviness and reduced mobility. It has the potential to be progressive and extremely
disfiguring and disabling for some patients. There is evidence that early intervention can
reduce the severity of lymphedema in breast cancer patients [28]. The diagnosis, best
interventions and awareness is still evolving for gynecologic cancers. The objectives of this
protocol were to estimate the incidence of lymphedema following surgery for endometrial,
cervical, or vulvar malignancies with sequential measures over time. Per the NCCN
guidelines, the surgery for endometrial and early cervical cancer patients allowed for the
removal of lymph nodes from similar anatomic locations. It was reassuring to identify the
incidence of lymphedema was also similar at 34% and 35%, for endometrial and cervical
cancer patients, respectively. Vulvar cancer patients have some of the highest reported
incidence of lymphedema [10–12], consistent with the higher 43% incidence in this study.
There are historic difficulties associated with lymphedema assessment concerning how it is
defined and measured [7, 29]. For gynecologic patients, the primary sites of lymphedema are
the lower extremities, and to a lesser extent, the vulva and mons areas, which are difficult to
assess with objective measurements [11] but may be detected by PRO questionnaires. Using
volumetric calculations to define lymphedema precludes conclusions gained from the PROs
linked to the secondary objectives of this protocol (Carter et al. in the accompanying
manuscript).

Author Manuscript

Lymphedema is commonly associated with the surgical disruption of the lymphatic channels
during a staging procedure [30]. Using bioimpedance techniques, lymphedema has been
documented in gynecologic cancer patients prior to surgery, which further complicates our
understanding of this disease [11]. The transitory nature of lymphedema was confirmed in
this study as 23% of the endometrial cohort had two or more transitions in their LVC during
their follow-up. Lymphedema severity changes over time and with treatment or activity [10]
and can be difficult to assess even in a prospective fashion In this study, there were PROs
declaring a diagnosis of lymphedema in some patients undergoing treatment who did not
have an LVC ≥10%. Relying solely on objective measurements may over-report the true
incidence of this dynamic process. In general, the incorporation of PROs into gynecologic
oncology research and clinical care has become widely accepted [31] and may be extremely
pertinent for lymphedema assessments [21, 32, 33].
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The risk factors associated with these gynecologic cancers and the subsequent onset of
lymphedema were also assessed. Because of the small numbers of cervical and vulvar cancer
patients, only the endometrial cohort underwent regression analysis and the monitored risk
factor must have preceded the onset of an LVC ≥10% in a patient who had at least 5 assessed
measurements. There have been many risk factors previously associated with lymphedema
that were not validated in this large prospective trial. For instance, pelvic radiation has
frequently been reported to be associated with an increased risk of lymphedema [9, 32, 34–
37]. But in this prospective trial, radiation was not found to be a risk factor through 2 years
of follow-up. The presence of metastatic disease in lymph nodes or advanced stage were
other risk factors not validated in this study [35, 38]. The lack of validation in these areas
may be reflective of the true differences of a large prospective trial or of issues with the
definitions and measurements used in this trial. A descriptive analysis was performed to
further evaluate several other risk factors. That analysis was limited to the endometrial
population as any results would be dominated by that population. In that analysis, this study
did identify that a lymph node dissection that exceeded 8 nodes was associated with a
significant increased risk of lymphedema development (p=0.0333).

Author Manuscript

These findings would corroborate the reported reduced risk of lymphedema associated with
a robotically assisted sentinel lymph node evaluation, in which fewer lymph nodes were
removed [39]. As 23.2% of those with ≤8 nodes removed still experienced some LVC, an
effort to manage these patients through treatment pathways that would further reduce the
number of lymph nodes removed without affecting overall survival warrants further
investigation. This study also identified a lower incidence of lymphedema associated with
advancing age, a finding that could not be corroborated in the literature. For this analysis,
there were a significant number of patients in their fifth and sixth decade of life. This
clustering did not allow a specific age risk cutoff to be defined during exploration. The
significance of age was identified when age was used as a continuous variable in the logistic
regression model and was the only significant variable for the whole population
The study had several strengths. It was the largest cohort of gynecologic cancer patients to
undergo a baseline assessment followed by sequential evaluation for lymphedema using
objective measurements over a 2-year interval. It standardized the assessment process and
increased the number of measurements in an attempt to improve the quality of the data.
Other strengths of this study include the 2 years of follow-up and its multi-institutional
nature, which give the findings broad applicability.

Author Manuscript

The study also had significant limitations. The large cohort size and multi-institutional
nature of the study were also weaknesses, as a large number of research associates were
involved in the assessments used to evaluate for LVC, the primary surrogate for diagnosing
lymphedema in this trial. Sequential measurements were tedious and labor-intensive.
Measurement accuracy was paramount to confident conclusions. Despite the training,
however, discrepancies were identified. The measurements were to be taken twice and
verified to be within 1 cm of each other. But 11.3% of the paired measurements reported had
a discrepancy greater than 1 cm. In addition, 32% of the patients had some reported variance
in leg length. If there was variance in leg length, then one could surmise that there may have
been variance in the location of the leg measurement. A hypothetical proximal movement of
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just 1.5 cm that was then propagated along the length of the leg may have skewed the
measurements enough to generate a 10% increase in LVC. The protocol analysis required
the completion of at least 5 measurements to be eligible for risk factor analysis. The risk
factor analysis was weakened by the large number of patients who were lost to follow-up,
with only half of the patients completing the 24 months of follow-up. Patients with a
complete data set were compared to those who were lost to follow-up. The additional
analysis could not identify any significant data inconsistencies or trends that would suggest
that those with lymphedema were more or less likely to complete the scheduled follow-up.
Another weakness was that the protocol did not require notification of the clinician when
there was an ≥10% LVC identified by the research staff. While it is not typical to
immediately communicate research results to the clinician, the failure to do so meant that
there was not an immediate concurrent clinical collaboration in those who manifested an
LVC by measurements or reported a new lymphedema diagnosis on the GCLQ. Therefore,
the lymphedema diagnosis was only assessed and documented through the patient-reported
questionnaire. This made it more difficult to draw conclusions when there were
discrepancies between an increase in LVC measurement that was not corroborated by a PRO
or a change in the GCLQ score (See Carter et al. in the accompanying manuscript).

Author Manuscript

Lymphedema is a complicated, dynamic process for which a “static” volumetric
measurement was applied in this study. Using volumetric measurements for LVC as a
surrogate potentially overestimated the true incidence of lymphedema while using PROs
likely underreported the true incidence. This opinion is not unique [7]. Perhaps the ideal
assessment strategy to assess LLE would include a less labor-intensive form of objective
limb measurement (bioimpedance) in conjunction with PROs of LLE symptoms (i.e.,
GCLQ). Since the presentation of the results of this study, an international panel of experts
met at the NCI to discuss controversies around circumferential measurements with the intent
to publish lymphedema assessment recommendations for future studies.
In conclusion, this is the largest prospective study to comprehensively assess lymphedema
and its associated risk factors in a cohort of gynecologic cancer patients. The findings
confirm that lymphedema is a common problem for these patients. The study also hightlights
some of the challenges with the diagnosis of this potentially debilitating problem.
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Refer to Web version on PubMed Central for supplementary material.
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RESEARCH HIGHLIGHTS
•

Lymphedema as defined by volume change ≥10% was found in 34% of
endometrial, 35% of cervical, and 43% of vulvar patients.

•

Regression analysis showed risk decreased with advanced age (p=0.0467) and
increased with a node count >8 (p=0.033).

•

Increase risk of lymphedema was not associated with radiation, advanced
stage or other commonly reported risk factors.

•

Final conclusions were weakened by 50% lost to follow-up and discrepancies
in measurements identified in 32% of patients.
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Figure 1. Flow Chart of Enrolled Patients.
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To be eligible for risk factor analysis, patients were required to have a baseline measurement
and at least four follow-up measurements.
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Author Manuscript

Characteristics of Enrolled Patients
Cancer Site
Characteristic

Endometrial
N

%

Cervical
N

Vulvar

%

N

Total

%

N

%

Age Group

Author Manuscript

20–29

1

0.1

9

6.5

0

30–39

18

2.5

40

29.0

1

2.4

59

6.5

40–49

49

6.7

47

34.1

6

14.3

102

11.2

50–59

266

36.2

20

14.5

17

40.5

303

33.2

60–69

274

37.3

16

11.6

8

19.0

298

32.6

70–79

113

15.4

5

3.6

7

16.7

125

13.7

80–89

12

1.6

1

0.7

3

7.1

16

1.8

1

0.1

0

0

0

0

1

0.1

≥90

0

10

1.1

Ethnicity
Hispanic or Latino

38

5.2

20

14.5

2

4.8

60

6.6

685

93.3

114

82.6

39

92.9

838

91.7

Refused to answer

6

0.8

2

1.4

0

0

8

0.9

Unknown/Not specified

5

0.7

2

1.4

1

2.4

8

0.9

Missing/Unknown

27

3.7

14

10.1

0

0

41

4.5

Asian

19

2.6

11

8.0

0

0

30

3.3

Black

68

9.3

6

4.3

4

9.5

78

8.5

Am. Indian/Alaskan Native

14

1.9

4

2.9

1

2.4

19

2.1

0

0

2

1.4

0

0

2

0.2

Non-Hispanic

Race

Native Hawaiian/PI

Author Manuscript

White

604

82.3

100

72.5

35

83.3

739

80.9

White/Asian

1

0.1

0

0

0

0

1

0.1

White/Indian

1

0.1

0

0

2

4.8

3

0.3

White/Native Hawaiian

0

0

1

0.7

0

0

1

0.1

734

80.3

138

15.1

42

4.6

914

100.0

Total
PI, Pacific Islander
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Table 3.

Author Manuscript

Comorbidities Identified in Evaluable Patients
Cancer Type

Vascular Insufficiency

Infection

Infection + Vascular Insufficiency

VTE

VTE + Infection

Endometrial (n=734)

3 (0.4%)

22 (3.0%)

1 (0.1%)

4 (0.5%

1 (0.1%)

9 (6.5%)

1 (0.7%)

1 (0.7%)

11 (26.2%)

2 (4.8%)

Cervical (n=138)
Vulvar (n=42)

1 (2.4%)

VTE, venous thromboembolism
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Table 4.

Author Manuscript

Lymphedema Diagnosis by Cancer Site
LVC

Cancer Site
Endometrial (%)

Cervical (%)

Vulvar (%)

<10% Increase

487 (66.4)

90 (65.2)

24 (57.1)

601

≥10% Increase

247 (33.7)

48 (34.8)

18 (42.9)

313

734

138

42

914

Total

Total

LVC, limb volume change

*

Lymphedema was defined as a LVC ≥10% from baseline.
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Table 6.
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Patient Compliance Over Time
Endometrial

Cervical

Vulvar

Baseline

734

138

42

Postop

669

124

38

3 months

576

103

30

6 months

543

104

34

9 months

504

91

31

12 months

512

88

29

18 months

448

83

21

24 months

400 (54%)

66 (48%)

17 (40%)

*

This table shows the number of patients who successfully completed planned follow-up at each assessment time point.
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Variables analyzed for association with a 10%, or greater, change in limb volume.

Author Manuscript

Effect

Estimate

95% Confidence

Limits

p value

Age*

0.816

0.670

0.994

0.0437

Surgical approach

0.875

0.537

1.426

0.5915

Blood Loss

1.002

0.978

1.027

0.8666

Number of Nodes

1.040

0.890

1.215

0.6237

Stage 2 vs 1

0.885

0.382

2.050

Stage 3 vs 1

1.421

0.662

3.050

Stage 4 vs 1

1.703

0.289

10.028

Race Black vs White

0.940

0.500

1.766

Race Other vs White

0.574

0.280

1.180

0.3189

Lymphocyst Formation

0.820

0.357

0.1.884

0.6399

Performance Status

1.096

0.546

2.201

0.7960

BMI 26–29 vs normal

0.846

0.487

1.471

BMI >30 vs normal

0.707

0.439

1.139

Presence of metastatic nodes

1.193

0.517

2.753

0.6795

External Beam Radiation

0.651

0.367

1.157

0.1435

Chemotherapy

1.010

0.621

1.642

0.9692

Post Surgical Infection

0.996

0.374

2.648

0.9932

VTE

1.211

0.170

8.655

0.8484

Use of Heparin

1.304

0.865

1.966

0.2043

Use of Compression Stockings

0.920

0.621

1.364

0.6794

0.7742

0.3331
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This anlaysis is of the endocmtrial cohort who had 5 or more measurements obtained. Surgical approach was analyzed as both a comparison of
open verses laparoscopic verses robotic and again as open verses minimally invasive techniques (laparoscopic and robotic combine). There wer no
associations between surgical approach and an increased LVC identified in this discriptive analysis. In the logistic regression analysis in those
endometrial patients who had at least 5 measurements, there was a reduction in risk of lymphedema associated with advancing age (p<0.04)

*

BMI, body mass index; VTE, venous thromboembolism
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